Open main menu
Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851406)
Watch
Edit
English
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
17463250
retrieved
13 November 2016
title
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
(English)
1 reference
stated in
PubMed
PubMed ID
17463250
retrieved
13 November 2016
main subject
cell line
0 references
lung cancer
1 reference
based on heuristic
inferred from title
author
Federico Cappuzzo
series ordinal
14
0 references
Tetsuya Mitsudomi
series ordinal
3
0 references
Lewis C. Cantley
series ordinal
18
0 references
Pasi A Jänne
series ordinal
19
object named as
Pasi A Jänne
0 references
Tony Mok
object named as
Tony Mok
series ordinal
15
1 reference
stated in
ORCID Public Data File 2021
author name string
Jeffrey A Engelman
series ordinal
1
0 references
Kreshnik Zejnullahu
series ordinal
2
0 references
Youngchul Song
series ordinal
4
0 references
Courtney Hyland
series ordinal
5
0 references
Joon Oh Park
series ordinal
6
0 references
Neal Lindeman
series ordinal
7
0 references
Christopher-Michael Gale
series ordinal
8
0 references
Xiaojun Zhao
series ordinal
9
0 references
James Christensen
series ordinal
10
0 references
Takayuki Kosaka
series ordinal
11
0 references
Alison J Holmes
series ordinal
12
0 references
Andrew M Rogers
series ordinal
13
0 references
Charles Lee
series ordinal
16
0 references
Bruce E Johnson
series ordinal
17
0 references
language of work or name
English
0 references
publication date
18 May 2007
0 references
published in
Science
0 references
volume
316
0 references
page(s)
1039-43
0 references
issue
5827
0 references
describes a project that uses
HCC827 GR1
0 references
HCC827 GR2
0 references
HCC827 GR5
0 references
HCC827 GR6
0 references
HCC827 GR7
0 references
HCC827 GR8
0 references
cites work
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Inhibition of the met receptor in mesothelioma
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
1 reference
stated in
COCI
retrieved
24 May 2022
reference URL
https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478
Identifiers
DOI
10.1126/SCIENCE.1141478
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
881527
OpenCitations bibliographic resource ID
881527
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
881527
PubMed ID
17463250
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
881527
ResearchGate publication ID
6366559
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
